CTIS2024-512980-29-00进行中（未招募）1 期
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group - PRESTO
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH0 个研究点目标入组 32 人开始时间: 2024年7月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patient* has given written informed consent., Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last study treatment if it is in the core treatment phase or for at least 3 months after last study treatment occurred in the maintenance phase. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy., Patient has a body weight > 30 kg, Patient has adequate hematological, hepatic and renal function as indicated by the following parameters: a. Leukocytes = 3,000/µL, platelets = 100,000/µL without transfusion, absolute neutrophil count (ANC) = 1,500/µL without granulocyte colonystimulating factor support, hemoglobin = 90 g/L (9 g/dL) - Patients may be transfused to meet this criterion. b. Bilirubin = 1.5 x upper limit of normal (ULN), aspartate transaminase and alanine transaminase = 2.5 x ULN, alkaline phosphatase = 2.5 x ULN c. Serum creatinine = 1.5 x ULN, or glomerular filtration rate > 45 mL/min (calculated using the Cockcroft-Gault formula) d. Serum albumin = 25 g/L (2.5 g/dL) e. For patients not receiving therapeutic anticoagulation: INR or aPTT = 1.5 x ULN; for patients receiving therapeutic anticoagulation: stable anticoagulant regimen, Patient has no human immunodeficiency virus (HIV) infection. NOTE: Patient with infection is eligible if he/she meets all the following criteria: a. CD4 count is =350 cells/µL, viral load is undetectable, and not taking prohibited cytochrome (CYP)-interacting medications b. Probable long-term survival with HIV if cancer were not present c. Stable on a highly active antiretroviral therapy (HAART) regimen for =4 weeks and willing to adhere to their HAART regimen with minimal overlapping toxicity and drug-drug interactions with the experimental agents in this study d. HIV is not multi-drug resistant e. Taking medication and/or receiving antiretroviral therapy that does not interact or have overlapping toxicities with the study medication, Patient is, in the investigator's judgement, willing and able to comply with the study protocol including the planned surgical treatment., Patient is = 18 years of age at time of signing the written informed consent., Patient has been diagnosed with histologically confirmed esophageal adenocarcinoma (including gastroesophageal junction (GEJ) (Siewert IIII)) with: a. cT2 N0 M0 stage or T1 N0 M0 stage and a given indication for radical surgical resection to current S3-guidelines (this includes patients with a given indication for radical surgery after endoscopic-resection of a cT1-2N0 M0 tumor [poor grading or L1/V1 invasion or basal R1 resection or deep submucosal infiltration]). b. tumor is considered medically and technically resectable., Tumor is tested (local testing with validated assays is sufficient, e.g., Dako PD-L1 IHC 22C3 or 28-8) for PD-L1 according to combined positive score (CPS) and results must be available prior study enrollment. In addition, tumor should be tested locally for MSI status and PD-L1 according to tumor proportion score (TPS) OR a representative tumor specimen that is suitable for central determination of PD-L1 TPS and MSI status is available. T
排除标准
- •Patient has known hypersensitivity to any component of the durvalumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein., Patient received an administration of a live, attenuated vaccine within four weeks prior to start of enrollment, or anticipation that such a live attenuated vaccine will be required during the study or within 30 days after the last dose of durvalumab., Patient had a prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA4, anti-PD-1, or anti- PD-L1 therapeutic antibodies., Patient had a treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within four weeks or five half-lives of the drug, whichever is longer, prior to study enrollment., atient had a treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed a.Intranasal, inhaled, topical steroids or local steroid injections b.Systemic corticosteroids at physiologic dose not to exceed 10mg/day of prednisone or its equivalent c.Steroids as premedication for hypersensitivity reactions, Patient has a significant cardiovascular disease, such as cardiac disease (New York Heart Association Class II or greater), myocardial infarction or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmias, or unstable angina., Patient has a clinically significant valvular defect., Patient has a history of malignancy other than EGA within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g. 5-year OS rate >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer., Patient has peripheral polyneuropathy = NCI CTCAE grade 2., Patient has uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN)., Patient has a serious infection requiring oral or IV antibiotics within 14 days prior to study enrollment., Patient has any known contraindication (including hypersensitivity) to docetaxel, 5-FU, leucovorin (calcium folinate), or oxaliplatin. In cases of pernicious anemia or other anemias due to vitamin B 12 deficiency, folinic acid (Leucovorin) is contraindicated and trial inclusion is not possible or only possible after compensation the anaemic status., Patient has chronic inflammatory bowel disease., Patient has clinically significant active gastrointestinal bleeding., Patient underwent major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment., Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results., Patient participated in another interventional clinical study = 30 days prior to study enrollment or participation in such a study at the same time as this study., Patient has taken an
研究者
相似试验
进行中（未招募）
1 期
Durvalumab-based immunotherapy in combination with chemoradiation for patients with early stage esophageal adenocarcinomaT1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgeryMedDRA version: 21.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001752-42-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH32
已完成
不适用
ChroPac-TrialDuodenum-preserving head resection versus pancreatico-duodenectomy for chronic pancreatitis of the head. A randomized controlled multicentre trialK86.0K86.1Alcohol-induced chronic pancreatitisOther chronic pancreatitischronic pancreatitisDRKS00000167Klinik für Allgemein-, Viszeral- und Transplantationschirurgie250
尚未招募
2 期
Comparision of three materials used after pulp therapyCTRI/2024/06/068984Mohil Kale
招募中
2 期
Organ-preserved tetra-modality therapy for patient having muscle invasive urothelial carcinoma 'OMC-regimen'Muscle invasive bladder carcinoma (MIBC) including regional lymph node metastasisJPRN-UMIN000012968Osaka medical college, Department of urology500
招募中
2 期
Organ preservation in patients with a good clinical response after neoadjuvant (chemo)radiation for rectal cancer: optimization of treatment strategies and defining the role of additional contact x-ray brachytherapy versus extending the waiting interval and local excision.rectal adenocarcinomarectal cancer1001799110017998NL-OMON52264Antoni van Leeuwenhoek Ziekenhuis168